Interpretation 2273
Tier 1|
|
|
Variants
Primary Sites
Tumor Types
Interpretation
BCL2 genomic Amplification may be associated with sensitivity to BCL2 inhibitors, however these inhibitors are currently undergoing clinical trials and their efficacy and/or lack of toxicity has not yet been demonstrated.
Citations
- Monni O, et al. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997;90(3):1168-74
- Kusumoto S, et al. Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "non-germinal center phenotype". Am J Surg Pathol 2005;29(8):1067-73
- Kendrick SL, et al. BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Hum Pathol 2014;45(10):2144-53
- Li L, et al. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia 2015;29(8):1702-12
Last updated: 2018-11-12 20:40:33 UTC